Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health (GH) is a leader in precision oncology, pioneering non-invasive liquid biopsy tests for cancer detection and monitoring. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's financial performance, clinical advancements, and strategic initiatives.
Access authoritative coverage of earnings reports, regulatory milestones, and technology innovations shaping cancer diagnostics. Our curated collection includes press releases on clinical trial results, partnership announcements, and peer-reviewed research developments directly from Guardant Health's communications.
Key updates cover FDA clearances for diagnostic assays, global commercialization efforts, and data partnerships advancing precision medicine. Stay informed about developments in molecular residual disease detection, expanded test indications, and reimbursement progress affecting healthcare adoption.
Bookmark this page for consolidated access to verified information about liquid biopsy advancements and GH's role in transforming cancer care through genomic insights. Check regularly for objective reporting on developments impacting both clinical practice and investment considerations.
Guardant Health Inc. (Nasdaq: GH) has expanded the availability of its innovative blood test, Guardant Reveal™, which detects minimal residual disease in colorectal, breast, and lung cancers without the need for a tissue biopsy. This test enables early identification of patients at higher risk for recurrence post-surgery, promising improved management of early-stage cancer. The Guardant Reveal test can be initiated three weeks post-surgery and outperforms traditional monitoring tools in predicting disease recurrence.
Guardant Health has received FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for patients with unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC). This test identifies patients who may benefit from the antibody drug conjugate ENHERTU. The Guardant360 CDx assay will enable oncologists to obtain comprehensive genomic results from a blood sample within a week, marking a significant advancement over traditional tissue biopsies. The HER2 mutations drive 2-4% of non-squamous NSCLC, representing a critical step for targeted cancer therapies.
Guardant Health (NASDAQ: GH) will participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference in Dana Point, CA. The management team is scheduled for a fireside chat on Wednesday, August 10, at 2:00 p.m. PT / 5:00 p.m. ET. Investors can access a live and archived webcast via the company's website. Guardant Health focuses on precision oncology, providing proprietary tests and analytics to improve cancer care. Its offerings include the Guardant360® suite for advanced cancer and the Shield™ test for cancer screening.
Guardant Health and Blueprint Medicines presented new data at the IASLC 2022 World Conference on Lung Cancer, revealing that the EGFR C797X mutation is a prevalent resistance mechanism to osimertinib for advanced non-small cell lung cancer (NSCLC) patients. The cumulative incidence of this mutation was found to be 12.5% after first-line treatment. The collaboration utilized the GuardantINFORM platform to analyze data from over 2,000 patients, emphasizing the need for next-generation EGFR inhibitors to combat C797X-driven resistance in NSCLC.
Guardant Health announced the presentation of studies at the IASLC 2022 World Conference on Lung Cancer in Vienna, focusing on its liquid biopsy tests' role in identifying treatment resistance mechanisms in lung cancer. Key findings will showcase the effectiveness of Guardant360, GuardantOMNI, and GuardantINFORM in advancing treatment strategies. Co-CEO Helmy Eltoukhy emphasized the significance of real-world data in improving patient outcomes. This event highlights Guardant Health's commitment to enhancing clinical decision-making in oncology.
Guardant Health reported Q2 2022 revenue of $109.1 million, marking a 19% increase from last year. Clinical and biopharma testing volumes surged by 40% and 65%, respectively. The company achieved Medicare coverage for Guardant Reveal™, enhancing access for colorectal cancer patients. Despite revenue growth, operating expenses rose 27% to $202.7 million, and net loss increased to $229.4 million. The firm expects 2022 revenue to reach $460 million to $470 million, indicating a 23% to 26% growth.
Guardant Health, Inc. (NASDAQ: GH) announced that its Guardant Reveal™ blood test for molecular residual disease (MRD) is now covered for fee-for-service Medicare patients in the US with stage II or III colorectal cancer (CRC). This coverage enables oncologists to detect circulating tumor DNA (ctDNA) in patients post-surgery, enhancing treatment decisions. The test marks a significant milestone as the first blood-only liquid biopsy for MRD testing in CRC. This decision complements existing Medicare coverage for other Guardant Health tests, boosting the company's position in precision oncology.
Guardant Health (NASDAQ: GH) will report its second quarter 2022 financial results after market close on August 4, 2022. A conference call is scheduled for 1:30 PM PT (4:30 PM ET) to discuss the results. The live audio webcast will be accessible via the company’s website and will be archived for future viewing.
Guardant Health is a leader in precision oncology, offering a range of tests for various cancer stages, including Guardant360 and Shield. These innovations aim to enhance cancer screening and treatment outcomes globally.
Guardant Health (Nasdaq: GH) has appointed Steve E. Krognes to its board of directors, enhancing its leadership amidst evolving market dynamics. Krognes brings over 20 years of experience in the biotech sector, having served in key roles including CFO at Denali Therapeutics and Genentech. His expertise in financial management and corporate strategy is expected to guide Guardant Health in its growth trajectory, particularly as it continues to advance its proprietary oncology tests and analytics aimed at improving cancer care.
Guardant Health (Nasdaq: GH) and Adicon Holdings Limited have formed a strategic partnership to provide comprehensive genomic profiling tests to biopharmaceutical companies in China. This collaboration will enable access to Guardant's liquid biopsy technologies, including Guardant360® and GuardantOMNI™, enhancing patient screening for clinical trials. Particularly, the partnership addresses the high cancer incidence in China, with the need for innovative therapies. This partnership reflects Guardant's commitment to advancing cancer care through cutting-edge diagnostics.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
